-
1Academic Journal
Authors: A. P. Seryakov, R. M. Akhmaev, A. A. Guryanova, A. A. Prokofieva, А. П. Серяков, Р. М. Ахмаев, А. А. Гурьянова, А. А. Прокофьева
Source: Pharmacogenetics and Pharmacogenomics; № 1 (2021); 33-37 ; Фармакогенетика и фармакогеномика; № 1 (2021); 33-37 ; 2686-8849 ; 2588-0527
Subject Terms: молекулярная диагностика, recurrent malignant tumors, molecular profiling, transcriptomics, RNA sequencing, Oncobox, experimental therapy, molecular diagnostics, рецидивирующие злокачественные опухоли, молекулярное профилирование, транскриптомика, РНК-секвенирование, Онкобокс, экспериментальная терапия
File Description: application/pdf
Relation: https://www.pharmacogenetics-pharmacogenomics.ru/jour/article/view/213/213; Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015 Mar 1;136(5):E359–386. DOI:10.1002/ijc.29210; Lacey JV, Chia VM, Rush BB, Carreon DJ, Richesson DA, Ioffe OB, Ronnett BM, Chatterjee N, Langholz B, Sherman ME, Glass AG. Incidence rates of endometrial hyperplasia, endometrial cancer and hysterectomy from 1980 to 2003 within a large prepaid health plan. Int J Cancer. 2012 Oct 15;131(8):1921–1929. DOI:10.1002/ijc.27457; Key TJ, Pike MC. The dose-effect relationship between ‘unopposed’ostrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br J Cancer. 1988 Feb;57(2):205–212. DOI:10.1038/bjc.1988.44.; Pike MC, Peters RK, Cozen W, Probst-Hensch NM, Felix JC, Wan PC, Mack TM. Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst. 1997 Aug 6;89(15):1110–1116. DOI:10.1093/jnci/89.15.1110.; Kaaks R, Lukanova A, Kurzer MS (2002). Obesity, endogenous hormones, and endometrial cancer risk: A synthetic review. Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1531–1543.; Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008 Feb 16;371(9612):569–578. DOI:10.1016/S0140-6736(08)60269-X.; Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol. 1995 Feb;85(2):304–313. DOI:10.1016/0029-7844(94)00383-O.; Purdie DM, Green AC. Epidemiology of endometrial cancer. Best Pract Res Clin Obstet Gynaecol. 2001 Jun;15(3):341–354. DOI:10.1053/beog.2000.0180.; Duska LR, Garrett A, Rueda BR, Haas J, Chang Y, Fuller AF. Endometrial cancer in women 40 years old or younger. Gynecol Oncol. 2001 Nov;83(2):388–393. DOI:10.1006/gyno.2001.6434.; Tarone RE, Chu KC. Age-period-cohort analyses of breast-, ovarian-, endometrial- and cervical-cancer mortality rates for Caucasian women in the USA. J Epidemiol Biostat. 2000;5(4):221–231.; Fung-Kee-Fung M, Dodge J, Elit L, Lukka H, Chambers A, Oliver T. Follow-up after primary therapy for endometrial cancer: A systematic review. Gynecol Oncol. 2006 Jun;101(3):520–529. DOI:10.1016/j.ygyno.2006.02.011.; Huijgens ANJ, Mertens HJMM. Factors predicting recurrent endometrial cancer. Facts Views Vis Obgyn. 2013;5(3):179-86.; Jeppesen MM, Jensen P T, Gilså Hansen D, Iachina M, Mogensen O. The nature of early-stage endometrial cancer recurrence—A national cohort study. Eur J Cancer. 2016 Dec;69:51–60. DOI:10.1016/j.ejca.2016.09.033.; Getz G, Gabriel SB, Cibulskis K, Lander E, Sivachenko A, Sougnez C, Lawrence M, Kandoth C, Dooling D, Fulton R, Fulton L, Kalicki-Veizer, J; McLellan MD, O’Laughlin M, Schmidt H, Wilson RK, Ye K, Li D, Ally A, Levine DA. Integrated genomic characterization of endometrial carcinoma. Nature. 2013 May 2;497(7447):67–73. DOI:10.1038/nature12113.; Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983 Feb;15(1):10–17. DOI:10.1016/0090-8258(83)90111-7.; Byron SA, Pollock PM. FGFR2 as a molecular target in endometrial cancer. Future Oncol. 2009 Feb;5(1):27–32. DOI:10.2217/14796694.5.1.27.; Sasada S, Yunokawa M, Takehara Y, Ishikawa M, Ikeda S, Kato T, Tamura K. Baseline risk of recurrence in stage I–II endometrial carcinoma. J Gynecol Oncol. 2018 Jan;29(1):e9. DOI:10.3802/jgo.2018.29.e9.; Morrow CP, Bundy BN, Kurman RJ, Creasman W T, Heller P, Homesley HD, Graham JE. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: A gynecologic oncology group study. Gynecol Oncol. 1991 Jan;40(1):55–65. DOI:10.1016/0090-8258(91)90086-k.; Carey MS, O’Connell GJ, Johanson CR, Goodyear MD, Murphy KJ, Daya DM, Schepansky A, Peloquin A, Lumsden BJ. Good outcome associated with a standardized treatment protocol using selective postoperative radiation in patients with clinical stage i adenocarcinoma of the endometrium. Gynecol Oncol. 1995 May;57(2):138–144. DOI:10.1006/gyno.1995.1115.; Mariani A, Webb MJ, Keeney GL, Haddock MG, Calori G, Podratz KC. Low-risk corpus cancer: Is lymphadenectomy or radiotherapy necessary? Am J Obstet Gynecol. 2000 Jun;182(6):1506–1519. DOI:10.1067/mob.2000.107335.; Güngördük K, Cuylan ZF, Kahramanoglu I, Oge T, Akbayir O, Dede M, Taşkln S, Ozgul N, Simsek T, Turan H, Gülseren V, Ozdemir A, Meydanll MM, Ayhan A. Risk Factors for Recurrence in Low-Risk Endometrial Cancer: A Case-Control Study. Oncol Res Treat. 2018;41(7-8):466–470. DOI:10.1159/000488112.; Versluis MA, De Jong RA, Plat A, Bosse T, Smit VT, Mackay H, Powell M, Leary A, Mileshkin L, Kitchener HC, Crosbie EJ, Edmondson RJ, Creutzberg CL, Hollema H, Daemen T, De Bock GH, Nijman HW. Prediction model for regional or distant recurrence in endometrial cancer based on classical pathological and immunological parameters. Br J Cancer. 2015 Sep 1;113(5):786–793. DOI:10.1038/bjc.2015.268.; Zeimet AG, Reimer D, Huszar M, Winterhoff B, Puistola U., Azim SA, Müller-Holzner E, Ben-Arie A, Van Kempen LC, Petru E, Jahn S, Geels YP, Massuger LF, Amant F, Polterauer S, Lappi-Blanco E, Bulten J, Meuter A, Tanouye S, Fogel M. L1CAM in early-stage type i endometrial cancer: Results of a large multicenter evaluation. J Natl Cancer Inst. 2013 Aug 7;105(15):1142–1150. DOI:10.1093/jnci/djt144.; Bosse T, Nout RA, Stelloo E, Dreef E, Nijman HW, Jürgenliemk- Schulz IM, Jobsen JJ, Creutzberg CL, Smit VTHBM. L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: Pooled PORTEC trial results. Eur J Cancer. 2014 Oct;50(15):2602–2610. DOI:10.1016/j.ejca.2014.07.014.; Werner HMJ, Trovik J, Halle MK, Wik E, Akslen LA, Birkeland E, Bredholt T, Tangen IL, Krakstad C, Salvesen HB. Stathmin protein level, a potential predictive marker for taxane treatment response in endometrial cancer. PLoS One. 2014 Feb 25;9(2):e90141. DOI:10.1371/journal.pone.0090141.; Odagiri T, Watari H, Hosaka M, Mitamura T, Konno Y, Kato T, Kobayashi N, Sudo S, Takeda M, Kaneuchi M, Sakuragi N. Multivariate survival analysis of the patients with recurrent endometrial cancer. J Gynecol Oncol. 2011 Mar 31;22(1):3–8. DOI:10.3802/jgo.2011.22.1.3.; Shim SH, Kim DY, Kim HJ, Lee SW, Park JY, Suh DS, Kim JH, Kim YM, Kim YT, Nam JH. Stratification of risk groups according to survival after recurrence in endometrial cancer patients. Medicine (Baltimore). 2017 May;96(21):e6920. DOI:10.1097/MD.0000000000006920.; Francis SR, Ager BJ, Do OA, Huang YHJ, Soisson AP, Dodson MK, Werner TL, Sause WT, Grant JD, Gaffney DK. Recurrent early stage endometrial cancer: Patterns of recurrence and results of salvage therapy. Gynecol Oncol. 2019 Jul;154(1):38–44. DOI:10.1016/j.ygyno.2019.04.676.; DeVita VT, Lawrence, TS, Rosenberg SA. DeVita, Hellman, and Rosenberg’s cancer: Principles & practice of oncology. In DeVita, Hellman, and Rosenberg’s Cancer: Principles & Practice of Oncology, Wolters Kluwer. 2018. p. 2170–2101.; Tkachev V, Sorokin M, Garazha A, Borisov N, Buzdin A. Oncobox Method for Scoring Efficiencies of Anticancer Drugs Based on Gene Expression Data. Methods Mol Biol. 2020;2063:235–255. DOI:10.1007/978-1-0716-0138-9_17; Sorokin M, Poddubskaya E, Baranova M, et al. RNA sequencing profiles and diagnostic signatures linked with response to ramucirumab in gastric cancer. Cold Spring Harb Mol Case Stud. 2020;6(2):a004945. Published 2020 Apr 1. DOI:10.1101/mcs.a004945; Poddubskaya E, Bondarenko A, Boroda A, et al. Transcriptomics- Guided Personalized Prescription of Targeted Therapeutics for Metastatic ALK-Positive Lung Cancer Case Following Recurrence on ALK Inhibitors. Front Oncol. 2019;9:1026. Published 2019 Oct 15. DOI:10.3389/fonc.2019.01026; Poddubskaya EV, Baranova MP, Allina DO, et al. Personalized prescription of imatinib in recurrent granulosa cell tumor of the ovary: case report. Cold Spring Harb Mol Case Stud. 2019;5(2):a003434. Published 2019 Apr 1. DOI:10.1101/mcs.a003434; Poddubskaya EV, Baranova MP, Allina DO, et al. Personalized prescription of tyrosine kinase inhibitors in unresectable metastatic cholangiocarcinoma. Exp Hematol Oncol. 2018;7:21. Published 2018 Sep 6. DOI:10.1186/s40164-018-0113-x; Moisseev A, Albert E, Lubarsky D, Schroeder D, Clark J. Transcriptomic and Genomic Testing to Guide Individualized Treatment in Chemoresistant Gastric Cancer Case. Biomedicines. 2020;8(3):67. Published 2020 Mar 23. DOI:10.3390/biomedicines8030067
-
2Academic Journal
Authors: O. O. Ryabaya, A. A. Prokofieva, D. A. Khochenkov, R. A. Akasov, S. V. Burov, E. A. Markvicheva, E. V. Stepanova, О. О. Рябая, А. А. Прокофьева, Д. А. Хоченков, Р. А. Акасов, С. В. Буров, Е. А. Марквичева, Е. В. Степанова
Source: Siberian journal of oncology; Том 18, № 3 (2019); 54-63 ; Сибирский онкологический журнал; Том 18, № 3 (2019); 54-63 ; 2312-3168 ; 1814-4861 ; 10.21294/1814-4861-2019-18-3
Subject Terms: рапамицин, epithelial-to-mesenchymal transition, 3D spheroids, experimental therapy, аутофагия, эпителиально-мезенхимальный переход, 3D-сфероиды, экспериментальная терапия
File Description: application/pdf
Relation: https://www.siboncoj.ru/jour/article/view/1096/637; Yang X., Yu D.D., Yan F., Jing Y.Y., Han Z.P., Sun K., Liang L., Hou J., Wei L.X. The role of autophagy induced by tumor microenvironment in different cells and stages of cancer. Cell Biosci. 2015 Mar 28; 5: 14. doi:10.1186/s13578-015-0005-2.; Gugnoni M., Sancisi V., Manzotti G., Gandolfi G., Ciarrocchi A. Autophagy and epithelial-mesenchymal transition: an intricate interplay in cancer. Cell Death Dis. 2016 Dec 8; 7(12): e2520. doi:10.1038/cddis.2016.415.; Kalluri R., Weinberg R.A. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009 Jun; 119(6): 1420–8. doi:10.1172/JCI39104.; Alonso S.R., Tracey L., Ortiz P., Pérez-Gómez B., Palacios J., Pollán M., Linares J., Serrano S., Sáez-Castillo A.I., Sánchez L., Pajares R., Sánchez-Aguilera A., Artiga M.J., Piris M.A., Rodríguez-Peralto J.L. A High-Throughput Study in Melanoma Identifies Epithelial-Mesenchymal Transition as a Major Determinant of Metastasis. Cancer Res. 2007 Apr 1; 67(7): 3450–60. doi:10.1158/0008-5472.CAN-06-3481.; Caramel J., Papadogeorgakis E., Hill L., Browne G.J., Richard G., Wierinckx A., Saldanha G., Osborne J., Hutchinson P., Tse G., Lachuer J., Puisieux A., Pringle J.H., Ansieau S., Tulchinsky E. A switch in the expression of embryonic EMT-inducers drives the development of malignant melanoma. Cancer Cell. 2013 Oct 14; 24(4): 466–80. doi:10.1016/j.ccr.2013.08.018.; Sullivan R.J., Fisher D.E. Understanding the Biology of Melanoma and Therapeutic Implications. Hematol Oncol Clin North Am. 2014 Jun; 28(3): 437–53. doi:10.1016/j.hoc.2014.02.007.; van’t Veer L.J., Burgering B.M., Versteeg R., Boot A.J., Ruiter D.J., Osanto S., Schrier P.I., Bos J.L. N-ras mutations in human cutaneous melanoma from sun-exposed body sites. Mol Cell Biol. 1989 Jul; 9(7): 3114–6.; Platz A., Egyhazi S., Ringborg U., Hansson J. Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site. Mol Oncol. 2008 Apr; 1(4): 395–405. doi:10.1016/j.molonc.2007.12.003.; Lin K., Baritaki S., Militello L., Malaponte G., Bevelacqua Y., Bonavida B. The Role of B-RAF Mutations in Melanoma and the Induction of EMT via Dysregulation of the NF-κB/Snail/RKIP/PTEN Circuit. Genes Cancer. 2010 May; 1(5): 409–420. doi:10.1177/1947601910373795.; Whipple C.A., Brinckerhoff C.E. BRAF(V600E) melanoma cells secrete factors that activate stromal fibroblasts and enhance tumourigenicity. Br J Cancer. 2014 Oct 14; 111(8): 1625–33. doi:10.1038/bjc.2014.452.; Salama A.K., Kim K.B. Trametinib (GSK1120212) in the treatment of melanoma. Expert Opin Pharmacother. 2013 Apr; 14(5): 619–27. doi:10.1517/14656566.2013.770475.; Ferguson J., Arozarena I., Ehrhardt M., Wellbrock C. Combination of MEK and SRC inhibition suppresses melanoma cell growth and invasion. Oncogene. 2013 Jan 3; 32(1): 86–96. doi:10.1038/onc.2012.25.; Fenouille N., Tichet M., Dufies M., Pottier A., Mogha A., Soo J.K., Rocchi S., Mallavialle A., Galibert M.-D., Khammari A., Lacour J.-P., Ballotti R., Deckert M., Tartare-Deckert S. The Epithelial-Mesenchymal Transition (EMT) Regulatory Factor SLUG (SNAI2) Is a Downstream Target of SPARC and AKT in Promoting Melanoma Cell Invasion. PLoS One. 2012; 7(7): e40378. doi:10.1371/journal.pone.0040378.; Thiery J.P., Sleeman J.P. Complex networks orchestrate epithelial– mesenchymal transitions. Nat Rev Mol Cell Biol. 2006 Feb; 7(2): 131–42. doi:10.1038/nrm1835.; Nathanson K.L., Martin A.M., Wubbenhorst B., Greshock J., Letrero R., D’Andrea K., O’Day S., Infante J.R., Falchook G.S., Arkenau H.T., Millward M., Brown M.P., Pavlick A., Davies M.A., Ma B., Gagnon R., Curtis M., Lebowitz P.F., Kefford R., Long G.V. Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436). Clin Cancer Res. 2013 Sep 1; 19(17): 4868–78. doi:10.1158/1078-0432.CCR-13-0827.; Mikhaylova I.N., Kovalevsky D.A., Morozova L.F., Golubeva V.A., Cheremushkin E.A., Lukashina M.I., Voronina E.S., Burova O.S., Utyashev I.A., Kiselev S.L., Demidov L. V., Beabealashvilli R.S., Baryshnikov A.Y. Cancer/testis genes expression in human melanoma cell lines. Melanoma Res. 2008 Oct; 18(5): 303–13. doi:10.1097/CMR.0b013e32830e391d.; Akasov R., Zaytseva-Zotova D., Burov S., Leko M., Dontenwill M., Chiper M., Vandamme T., Markvicheva E. Formation of multicellular tumor spheroids induced by cyclic RGD-peptides and use for anticancer drug testing in vitro. Int J Pharm. 2016 Jun 15; 506(1–2): 148–57. doi:10.1016/j.ijpharm.2016.04.005.; Ryabaya O., Prokofieva A., Khochenkov D., Abramov I., Zasedatelev A., Stepanova E. Inhibition of endoplasmic reticulum stress-induced autophagy sensitizes melanoma cells to temozolomide treatment. Oncol Rep. 2018 Jul; 40(1): 385–394. doi:10.3892/or.2018.6430.; Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 1984; 22: 27–55.; Calero R., Morchon E., Martinez-Argudo I., Serrano R. Synergistic anti-tumor effect of 17AAG with the PI3K/mTOR inhibitor NVP-BEZ235 on human melanoma. Cancer Lett. 2017 Oct 10; 406: 1–11. doi:10.1016/j.canlet.2017.07.021.; Carlino M.S., Todd J.R., Gowrishankar K., Mijatov B., Pupo G.M., Fung C., Snoyman S., Hersey P., Long G. V., Kefford R.F., Rizos H. Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma. Mol Oncol. 2014 May; 8(3): 544–54. doi:10.1016/j.molonc.2014.01.003.; Schlegel N.C., von Planta A., Widmer D.S., Dummer R., Christofori G. PI3K signalling is required for a TGFβ-induced epithelial-mesenchymallike transition (EMT-like) in human melanoma cells. Exp Dermatol. 2015 Jan; 24(1): 22–8. doi:10.1111/exd.12580.; Haagensen E.J., Kyle S., Beale G.S., Maxwell R.J., Newell D.R. The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition. Br J Cancer. 2012 Apr 10; 106(8): 1386–94. doi:10.1038/bjc.2012.70.; Wang X., Chen K., Yu Y., Xiang Y., Kim J.H., Gong W., Huang J., Shi G., Li Q., Zhou M., Sayers T., Tewary P., Gao B., Wang J.M. Metformin sensitizes lung cancer cells to treatment by the tyrosine kinase inhibitor erlotinib. Oncotarget. 2017 Nov 21; 8(65): 109068–109078. doi:10.18632/oncotarget.22596.; Betz C., Hall M.N. Where is mTOR and what is it doing there? J Cell Biol. 2013 Nov 25; 203(4): 563–74. doi:10.1083/jcb.201306041.; Vultur A., Villanueva J., Krepler C., Rajan G., Chen Q., Xiao M., Li L., Gimotty P.A., Wilson M., Hayden J., Keeney F., Nathanson K.L., Herlyn M. MEK inhibition affects STAT3 signaling and invasion in human melanoma cell lines. Oncogene. 2014 Apr 3; 33(14): 1850–61. doi:10.1038/onc.2013.131.; Solit D.B., Garraway L.A., Pratilas C.A., Sawai A., Getz G., Basso A., Ye Q., Lobo J.M., She Y., Osman I., Golub T.R., Sebolt-Leopold J., Sellers W.R., Rosen N. BRAF mutation predicts sensitivity to MEK inhibition. Nature. 2006 Jan 19; 439(7074): 358–62. doi:10.1038/nature04304.; Gilmartin A.G., Bleam M.R., Groy A., Moss K.G., Minthorn E.A., Kulkarni S.G., Rominger C.M., Erskine S., Fisher K.E., Yang J., Zappacosta F., Annan R., Sutton D., Laquerre S.G. Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition. Clin Cancer Res. 2011 Mar 1; 17(5): 989–1000. doi:10.1158/1078-0432.CCR-10-2200.; Vu H.L., Rosenbaum S., Capparelli C., Purwin T.J., Davies M.A., Berger A.C., Aplin A.E. MIG6 Is MEK Regulated and Affects EGF-Induced Migration in Mutant NRAS Melanoma. J Invest Dermatol. 2016 Feb; 136(2): 453–463. doi:10.1016/j.jid.2015.11.012.; Leight J.L., Tokuda E.Y., Jones C.E., Lin A.J., Anseth K.S. Multifunctional bioscaffolds for 3D culture of melanoma cells reveal increased MMP activity and migration with BRAF kinase inhibition. Proc Natl Acad Sci U S A. 2015 Apr 28; 112(17): 5366–71. doi:10.1073/pnas.1505662112.; Ge X., Fu Y.M., Meadows G.G. U0126, a mitogen-activated protein kinase kinase inhibitor, inhibits the invasion of human A375 melanoma cells. Cancer Lett. 2002; 179(2): 133–140.; Qiang L., He Y.-Y. Autophagy deficiency stabilizes TWIST1 to promote epithelial-mesenchymal transition. Autophagy. 2014 Oct 1; 10(10): 1864–5. doi:10.4161/auto.32171.; Shen H., Yin L., Deng G., Guo C., Han Y., Li Y., Cai C., Fu Y., Liu S., Zeng S. Knockdown of Beclin-1 impairs epithelial-mesenchymal transition of colon cancer cells. J Cell Biochem. 2018 Aug; 119(8): 7022–7031. doi:10.1002/jcb.26912.; Nitta T., Sato Y., Ren X.S., Harada K., Sasaki M., Hirano S., Nakanuma Y. Autophagy may promote carcinoma cell invasion and correlate with poor prognosis in cholangiocarcinoma. Int J Clin Exp Pathol. 2014 Jul 15; 7(8): 4913–21.; Chen Y., Lu Y., Lu C., Zhang L. Beclin-1 expression is a predictor of clinical outcome in patients with esophageal squamous cell carcinoma and correlated to hypoxia-inducible factor (HIF)-1alpha expression. Pathol Oncol Res. 2009 Sep; 15(3): 487–93. doi:10.1007/s12253-008-9143-8.; Ko Y.H., Cho Y.-S., Won H.S., Jeon E.K., An H.J., Hong S.U., Park J.H., Lee M.A. Prognostic significance of autophagy-related protein expression in resected pancreatic ductal adenocarcinoma. Pancreas. 2013 Jul; 42(5): 829–35. doi:10.1097/MPA.0b013e318279d0dc.; Masuda G.O., Yashiro M., Kitayama K., Miki Y., Kasashima H., Kinoshita H., Morisaki T., Fukuoka T., Hasegawa T., Sakurai K., Toyokawa T., Kubo N., Tanaka H., Muguruma K., Masaichi O., Hirakawa K. Clinicopathological Correlations of Autophagy-related Proteins LC3, Beclin 1 and p62 in Gastric Cancer. Anticancer Res. 2016; 36(1): 129–136.; https://www.siboncoj.ru/jour/article/view/1096
-
3Academic Journal
Authors: Иванов, Леонид, Алексеева, Наталья, Колотилова, Марина
Subject Terms: ЖЕЛЧЬ, ХОЛЕЛИТИАЗ, ЭКСПЕРИМЕНТАЛЬНАЯ ТЕРАПИЯ, ЭКСПЕРИМЕНТАЛЬНАЯ ПРОФИЛАКТИКА
File Description: text/html
-
4Academic Journal
Authors: Шамова, Т., Лебейко, Т.
Subject Terms: РАССЕЯННЫЙ СКЛЕРОЗ, ЭКСПЕРИМЕНТАЛЬНАЯ ТЕРАПИЯ, ИММУНОМОДУЛЯТОРЫ, ИММУНОСУПРЕССОРЫ
File Description: text/html
-
5Academic Journal
Source: Медицинский альманах.
Subject Terms: 03 medical and health sciences, 0302 clinical medicine, ЖЕЛЧЬ, ХОЛЕЛИТИАЗ, ЭКСПЕРИМЕНТАЛЬНАЯ ТЕРАПИЯ, ЭКСПЕРИМЕНТАЛЬНАЯ ПРОФИЛАКТИКА
File Description: text/html
-
6Academic Journal
Authors: Афанасьев, А., Коваленко, А., Колбасов, С., Любимов, Ю., Саватеева, Т.
Subject Terms: ОСМОФУЗИН, ОТЕК МОЗГА, ЭКСПЕРИМЕНТАЛЬНАЯ ТЕРАПИЯ
File Description: text/html
-
7Academic Journal
Authors: Красникова, И., Четверикова, Татьяна, Куклина, Людмила, Колбасеева, О., Макарова, Н., Носкова, Л., Медведева, С., Александрова, Г., Грищенко, А.
Subject Terms: ЖЕЛЕЗОДЕФИЦИТНАЯ АНЕМИЯ, ЭКСПЕРИМЕНТАЛЬНАЯ АНЕМИЯ, МОДЕЛИРОВАНИЕ АНЕМИИ, ЭКСПЕРИМЕНТАЛЬНАЯ ТЕРАПИЯ, ФЕРРОГАЛ
File Description: text/html
-
8Academic Journal
Source: Журнал Гродненского государственного медицинского университета.
Subject Terms: РАССЕЯННЫЙ СКЛЕРОЗ, ЭКСПЕРИМЕНТАЛЬНАЯ ТЕРАПИЯ, ИММУНОМОДУЛЯТОРЫ, ИММУНОСУПРЕССОРЫ, 3. Good health
File Description: text/html
-
9Academic Journal
Source: Психофармакология и биологическая наркология.
Subject Terms: 3. Good health, ОСМОФУЗИН, ОТЕК МОЗГА, ЭКСПЕРИМЕНТАЛЬНАЯ ТЕРАПИЯ
File Description: text/html
-
10Academic Journal
Source: Сибирский медицинский журнал (Иркутск).
Subject Terms: 0301 basic medicine, 0303 health sciences, 03 medical and health sciences, ЖЕЛЕЗОДЕФИЦИТНАЯ АНЕМИЯ, ЭКСПЕРИМЕНТАЛЬНАЯ АНЕМИЯ, МОДЕЛИРОВАНИЕ АНЕМИИ, ЭКСПЕРИМЕНТАЛЬНАЯ ТЕРАПИЯ, ФЕРРОГАЛ, 3. Good health
File Description: text/html
-
11Academic Journal
Authors: Ульянов, В. А., Гайдамака, Т. Б., Макарова, М. Б., Давтян, Л. Л., Мовчан, Б. А., Скобеева, В. М., Ulianov, V. A., Gaydamaka, T. B., Makarova, M. B., Davtyan, L. L., Movchan, B. A., Skobeeva, V. M.
Subject Terms: бактериальный кератит, наночастицы серебра, экспериментальная терапия, bacterial keratitis, silver nanoparticles, experimental treatment
File Description: application/pdf
Relation: Влияние наночастиц серебра размером 30 нм на клиническое течение экспериментального бактериального кератита средней степени тяжести / В. А. Ульянов, Т. Б. Гайдамака, М. Б. Макарова [и др.] // Інтегративна антропологія. – 2018. – № 1. – С. 26–33.; http://repo.odmu.edu.ua:80/xmlui/handle/123456789/3301
Availability: http://repo.odmu.edu.ua:80/xmlui/handle/123456789/3301
-
12Academic Journal
Authors: Романова, Ю. Г., Шнайдер, С. А., Бреус, В. Е., Бреус, В. Є., Romanova, Y. G., Schnаider, S. A, Breus, V. E.
Subject Terms: слизистая оболочка полости рта, адаптация, экспериментальная терапия, слизова оболонка порожнини рота, адаптація, експериментальна терапія, oral mucosa, adaptation, experimental therapy
File Description: application/pdf
Relation: Романова Ю. Г. Морфологические исследования слизистой оболочки полости рта крыс, при воздействии мономера метилметакрилата и геля "Профиал" / Ю. Г. Романова, С. А. Шнайдер, В. Е. Бреус // Вісник стоматології. – 2014. – № 2. – С. 2–4.; http://repo.odmu.edu.ua:80/xmlui/handle/123456789/4273
Availability: http://repo.odmu.edu.ua:80/xmlui/handle/123456789/4273
-
13Dissertation/ Thesis
Authors: Розанов Всеволод Анатольевич
Subject Terms: диссертация, биохимия, ГАМК-шунт, биология, компенсация метаболическая, медицина, мозг, мозг головной, экспериментальная терапия, экстремальные состояния
Availability: https://repository.rudn.ru/records/dissertation/record/47907/
-
14Dissertation/ Thesis
Authors: Розанов Всеволод Анатольевич
Subject Terms: автореферат диссертации, биохимия, ГАМК-шунт, биология, компенсация метаболическая, медицина, мозг, мозг головной, экспериментальная терапия, экстремальные состояния
Availability: https://repository.rudn.ru/records/dissertation/record/83322/
